Nuveen LLC Invests $10.68 Million in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Nuveen LLC has made a new investment in BioCryst Pharmaceuticals, acquiring 1,423,646 shares valued at approximately $10.68 million, representing about 0.68% of the company.
• BioCryst Pharmaceuticals recently reported a 49.5% increase in revenue year-over-year, with earnings per share of $0.15, significantly exceeding estimates of $0.03.
• Analysts are optimistic about BioCryst, with nine analysts rating it as a "Buy" and one as a "Hold," and a consensus target price of $16.70.

Nuveen LLC bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,423,646 shares of the biotechnology company's stock, valued at approximately $10,677,000. Nuveen LLC owned 0.68% of BioCryst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of BioCryst Pharmaceuticals by 64.5% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,042,424 shares of the biotechnology company's stock worth $7,818,000 after acquiring an additional 408,560 shares during the period. Headlands Technologies LLC purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $32,000. New Age Alpha Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $62,000. R Squared Ltd increased its position in shares of BioCryst Pharmaceuticals by 84.2% during the first quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company's stock worth $88,000 after acquiring an additional 5,335 shares during the period. Finally, Jupiter Asset Management Ltd. increased its holdings in BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock valued at $16,117,000 after buying an additional 971,040 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director directly owned 65,352 shares in the company, valued at $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is currently owned by company insiders.

BioCryst Pharmaceuticals Stock Performance

BCRX traded down $0.05 during trading on Thursday, hitting $8.47. The stock had a trading volume of 1,798,118 shares, compared to its average volume of 3,153,819. The company has a market capitalization of $1.78 billion, a PE ratio of -47.05, a PEG ratio of 1.94 and a beta of 1.10. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31. The stock has a 50 day simple moving average of $8.70 and a two-hundred day simple moving average of $8.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. BioCryst Pharmaceuticals's revenue was up 49.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) earnings per share. On average, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BCRX. JPMorgan Chase & Co. lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Needham & Company LLC reissued a "buy" rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Wedbush lifted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Finally, Bank of America lifted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, July 1st. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.